Sciens Building Solutions Acquires Another New York Company

SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Sciens Building Solutions (“Sciens”) today announced it has welcomed Latham, New York-based Fire Security & Sound Systems (FS&S) to its growing portfolio of companies. This is the latest acquisition announcement from Sciens, which expands their Northeast presence where it has 10 existing Divisions. FS&S will add to […]

Symbotic (SYM) Accused of Misleading Investors with Inflated Revenues – Hagens Berman

(NasdaqGM:SYM), SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Symbotic Inc. (NASDAQ: SYM), a Wilmington, Mass.-based automation technology company, has filed restated financial statements for three fiscal 2024 quarters, revealing significant errors in its previously reported revenue and profitability figures. The restatements, filed on December 4, follow the revelation of accounting errors last month and

Johnson Outdoors to Release Fiscal 2025 First Quarter Results on February 3, 2025

(NASDAQ:JOUT), RACINE, Wis., Jan. 22, 2025 (GLOBE NEWSWIRE) — JOHNSON OUTDOORS INC. (Nasdaq: JOUT), a leading global innovator of outdoor recreation equipment and technology, will release financial results for the Fiscal 2025 first quarter on Monday, February 3, 2025, before market open that day. The Company will host a conference call and audio webcast shortly

ASP Isotopes (ASPI) Continue to Slump Despite Response to Short Seller Report – Hagens Berman

(NASDAQ:ASPI), SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Shares of ASP Isotopes Inc. (NASDAQ: ASPI) have continue their downward spiral falling 16% over the past five days, despite the company having issued a rebuttal to a scathing report from activist short-seller Fuzzy Panda Research. The stock price trades at $4.52 per share, marking a

Kyverna Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX

NEW YORK, NY / ACCESSWIRE / January 22, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=124440&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

Five9, Inc. Securities Fraud Lawsuit Pending

WASHINGTON, DC / ACCESS Newswire / January 22, 2025 / Cohen Milstein alerts investors that a complaint was filed on December 4, 2024 in the U.S. District Court for the Northern District of California against Five9, Inc. ("Five9" or the "Company") (Nasdaq:FIVN). The complaint alleges that Five9 and its Chair and CEO, Michael Burkland, and

Colendi’s Bold Play: Bridging AI, Banking, and Financial Accessibility

LONDON, UK / ACCESS Newswire / January 22, 2025 / In the rapid evolution of financial technology, few companies have made waves quite like Colendi. This Turkish fintech trailblazer has captured international attention, not only for its audacious ambition but for its ability to deliver results that challenge the status quo. With Türkiye’s first full

InventHelp Inventor Develops New Socket Plug Tool (HAD-336)

“I'm a plumber and have personally struggled with accessing, gripping, and turning the threaded plugs forcleanouts used in sewer and drain lines. I thought there could be a better way,” said an inventor, from Opa Locka, Fla., “so I invented the SOCKET PLUG TOOL. My design would fit secure over the plug for gripping and

AstraZeneca (AZN) Reels from China Investigation and Investor Suit- Hagens Berman

(NASDAQ:AZN), SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) — AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman

(NASDAQ:BIOA), SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) — BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and prospects of a key drug candidate before its initial public offering last September. Hagens Berman urges investors who

Scroll to Top